Individualized, heterologous chimpanzee adenovirus and self-amplifying mRNA neoantigen vaccine for advanced metastatic solid tumors: phase 1 trial interim results Research Published on 2022-08-152022-10-05 Journal: Nature Medicine [Category] 변종, 유전자 메커니즘, 임상, 치료법, [키워드] Adenovirus adverse event analyses Analysis benefit Biomarker CD8 T cell circulating Colorectal cancer Combination CPI diarrhea disease DNA dose Endpoint fatigue feasibility feasible Heterologous immune inhibitor injection site pain Ipilimumab limit long-lasting mRNA Musculoskeletal nivolumab Patient phase 1 trial primary endpoint Pyrexia randomized studies reactivity regimen responses Safe Safety secondary solid tumor statistical survival therapy Tolerability toxicities transaminase translational Tumor vaccination Vaccine viral particle were assessed [DOI] 10.1038/s41591-022-01937-6 [Article Type] Research
Safety, Effectiveness, and Immunogenicity 6 Months After BNT162B2 mRNA Vaccine in Frail Nursing Home ResidentsObservational Study Published on 2022-07-012022-10-04 Journal: Drugs & aging [Category] Coronavirus, COVID19(2023년), SARS, 임상, [키워드] acute respiratory syndrome Adverse drug reaction adverse events Adverse reaction age association Binary logistic regression Care Characteristics clinical cognitive collected Comorbidity coronavirus coronavirus disease COVID-19 COVID-19 infection effective Effectiveness elderly evaluate evaluated fatigue female frailty functional headache home Hospital admissions immunogenicity incidence index Loss Month Mortality MOST mRNA mRNA vaccine Nursing Occurrence Older age Palliative care participant pathology percentage positive serology Pyrexia resident Safety SARS-CoV-2 SARS-COV-2 infection scale serious adverse reaction severity Spain vaccination Vaccine was tested [DOI] 10.1007/s40266-022-00959-6 PMC 바로가기 [Article Type] Observational Study
Efficacy and safety of the BNT162b2 mRNA COVID-19 vaccine in participants with a history of cancer: subgroup analysis of a global phase 3 randomized clinical trialClinical Trial Published on 2022-03-012022-10-05 Journal: Vaccine [Category] SARS, 임상, [키워드] AEs baseline BNT162b2 BNT162b2 mRNA BNT162b2 vaccine Cancer clinical clinical trials COVID-19 COVID-19 pandemic COVID-19 vaccine death Efficacy Efficacy and safety excluded fatigue Follow-up follow-up time high risk Hospitalization immunosuppressive incidence rate individual Infection Injection-site pain malignancy Melanoma MOST neoplasm Neoplasms observer-blinded outcomes participant Participants Phase 3 Placebo placebo recipient placebo-controlled Prostate Pyrexia Randomized randomized clinical trial reactogenicity event receiving reported Safe Safety subgroup analysis therapy Trial unblinding Vaccine were excluded [DOI] 10.1016/j.vaccine.2021.12.046 PMC 바로가기 [Article Type] Clinical Trial
COVID-19 vaccine reactogenicity – A cohort event monitoring study in the Netherlands using patient reported outcomesArticle Published on 2022-02-112023-07-07 Journal: Vaccine [Category] COVID19(2023년), [키워드] AEFI COVID-19 vaccine Drug safety Patient reported outcomes pharmacovigilance Postmarketing Pyrexia reactogenicity [DOI] 10.1016/j.vaccine.2022.01.013 PMC 바로가기
Induction of CD73 prevents death after emergency open aortic surgery for a ruptured abdominal aortic aneurysm: a randomized, double-blind, placebo-controlled studyArticle Published on 2022-02-032022-10-04 Journal: Scientific Reports [Category] 바이오마커, [키워드] 95% CI adverse event all-cause mortality Analysis Aneurysm anticipated aortic aneurysm ARDS baseline blocked with CD73 cluster of differentiation concerning concomitant use congestive heart failure D30 death demonstrated diagnosed double-blind drug-drug interaction Efficacy and safety exclusion criteria glucocorticoid Hemorrhagic IFN IMPROVE induction initial interim analysis intestinal intravenous Ischemia Liver cirrhosis Major malignant disease matching placebo mechanism Neutralizing antibodies neutralizing antibody outcome outcome measure parallel group Patient Placebo placebo-controlled study postoperative Prevent Pyrexia Randomized randomized patient Registered renal replacement therapy reported serum Shock statistically significant difference suggested surgery survival survived treated Treatment treatment group Trial up-regulating [DOI] 10.1038/s41598-022-05771-1 PMC 바로가기 [Article Type] Article
Impact of SARS-CoV-2 Genetic Blueprints on the Oral Manifestation of COVID-19: A Case ReportCase Report Published on 2021-12-162022-10-31 Journal: Global Medical Genetics [Category] COVID-19, [키워드] ACE2 ACE2 receptor acute respiratory syndrome Ageusia angiotensin-converting enzyme-2 Anosmia blueprint Case report cause coronavirus coronavirus disease cough COVID-19 dentist diagnosed with COVID-19 diarrhea Diseases Dyspnea fatigue genomic gingival inflammation Impact include life threatening manifestation myalgia nausea oral oral disease oral manifestation pathway Patient physician positive-sense Pyrexia receptor report reported RNA SARS-CoV-2 Symptom symptoms of COVID-19 the disease these symptom Treatment virus viruses [DOI] 10.1055/s-0041-1735538 PMC 바로가기 [Article Type] Case Report
Comparison of Experimental Middle East Respiratory Syndrome Coronavirus Infection Acquired by Three Individual Routes of Infection in the Common MarmosetPathogenesis and Immunity Published on 2021-12-152022-10-30 Journal: Journal of Virology [Category] COVID-19, COVID19(2023년), MERS, SARS, [키워드] Callithrix jacchus Acquired acute respiratory syndrome aerosol route Aerosols animal animal model breathing difficulties Callithrix caused challenge characterized common complications Concentration coronavirus cough demonstrated described disease emerging disease England Erasmus Fatality rate Fever Host host response Human Immunological response individual interstitial pneumonia intranasal Lung disease lung tissue Macrophage macrophages marmoset medical countermeasure MERS-CoV Middle East Middle East respiratory syndrome Mild neutrophil function Neutrophils Pneumonia Pyrexia renal respiratory respiratory syndrome coronavirus route SARS-CoV-2 severity Shortness of breath strain syndrome the disease throat swab upregulation Viable virus were used [DOI] 10.1128/jvi.01739-21 PMC 바로가기 [Article Type] Pathogenesis and Immunity
Safety, Virologic Efficacy, and Pharmacokinetics of CT-P59, a Neutralizing Monoclonal Antibody Against SARS-CoV-2 Spike Receptor-Binding Protein: Two Randomized, Placebo-Controlled, Phase I Studies in Healthy Individuals and Patients With Mild SARS-CoV-2 InfectionSARS-CoV-2 스파이크 수용체 결합 단백질에 대한 중화 단일클론항체 CT-P59의 안전성, 바이러스학적 효능 및 약동학: 건강한 개인 및 경증 SARS-CoV-2 환자를 대상으로 한 무작위, 위약 대조, 1상 연구 2건 전염병Randomized Controlled Trial Published on 2021-10-012022-09-12 Journal: Clinical therapeutics [Category] MERS, SARS, 임상, 진단, [키워드] Adverse adverse event AEs Against antibody Antiviral C-reactive protein cellular entry Clinical efficacy Cohort Common Terminology Criteria COVID-19 CT-P59 dose double-blind elevated end point enrolled examined exhibited headache healthy in healthy individual individual mild SARS-CoV-2 infection monoclonal monoclonal antibody Neutralizing neutralizing monoclonal antibody pathologic Patient pharmacokinetic pharmacokinetics phase Placebo placebo-controlled Pyrexia Randomized receive receiving reduce reductions in regdanvimab reported Safety safety profile SARS-CoV-2 secondary single ascending dose spike Time to recovery Tolerability viral titer [DOI] 10.1016/j.clinthera.2021.08.009 PMC 바로가기 [Article Type] Randomized Controlled Trial
Host Cell and SARS-CoV-2-Associated Molecular Structures and Factors as Potential Therapeutic Targets숙주 세포 및 SARS-CoV-2-관련 분자 구조 및 잠재적인 치료 표적으로서의 요인Review Published on 2021-09-152022-09-12 Journal: Cells [Category] SARS, 진단, [키워드] ACE2 acute respiratory syndrome angiotensin-converting enzyme 2 caused cellular entry characterized Clinical outcome CLRs coronavirus coronavirus disease 19 cough COVID-19 Critical diarrhea Dyspnoea Factor family Coronaviridae furin genus Betacoronavirus hemoptysis Host host cell host cell surface humans infect Infection lymphopenia mammals molecular interaction Nidovirale non-structural protein Pathogenesis positive-sense Potential protease Protein Pyrexia receptor receptors regimen SARS-CoV-2 single-stranded RNA virus Structure Symptoms target the disease therapeutic targeting therapeutically target TMPRSS2 transmembrane serine protease viral disease virus [DOI] 10.3390/cells10092427 PMC 바로가기 [Article Type] Review
Favipiravir Versus Arbidol for Clinical Recovery Rate in Moderate and Severe Adult COVID-19 Patients: A Prospective, Multicenter, Open-Label, Randomized Controlled Clinical TrialPharmacology Published on 2021-09-022022-10-31 Journal: Frontiers in Pharmacology [Category] COVID-19, [키워드] 1:1 addition Adverse adverse event antiviral therapy Arbidol assigned auxiliary caused clinical clinical recovery collected conducted contributed Controlled coronavirus disease cough COVID-19 COVID-19 patient COVID-19 patients Drug administration Effect effective Efficacy and safety enrolled Favipiravir IMPROVE initial symptom latency mechanical ventilation Mild Multicenter trial noninvasive Open-label oxygen saturation Oxygen therapy Patient patients with COVID-19 Primary outcome Prospective Pyrexia Randomized Randomized controlled trial Randomly Rate receive respiratory frequency Safety SARS-CoV-2 Secondary outcomes serum significantly therapy treat Treatment umifenovir umifenovir (arbidol) uric acid Ventilation was increased [DOI] 10.3389/fphar.2021.683296 PMC 바로가기 [Article Type] Pharmacology